Raymond James Downgrades Apellis Pharmaceuticals to Outperform, Lowers Price Target to $52

Benzinga · 5d ago
Raymond James analyst Ryan Deschner downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Strong Buy to Outperform and lowers the price target from $75 to $52.